1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here is one cash-producing company that excels at turning cash into shareholder value and two that may struggle to keep up.
Two Stocks to Sell:
Live Nation (LYV)
Trailing 12-Month Free Cash Flow Margin: 6.6%
Owner of Ticketmaster and operator of music festival EDC, Live Nation (NYSE:LYV) is a company specializing in live event promotion, venue management, and ticketing services for concerts and shows.
Why Does LYV Fall Short?
- Annual sales growth of 5.3% over the last two years lagged behind its consumer discretionary peers as its large revenue base made it difficult to generate incremental demand
- Subpar operating margin of 4.3% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 1.1 percentage points
Live Nation is trading at $156.91 per share, or 122.4x forward P/E. Dive into our free research report to see why there are better opportunities than LYV.
GoodRx (GDRX)
Trailing 12-Month Free Cash Flow Margin: 20.6%
Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ:GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.
Why Should You Sell GDRX?
- Muted 2.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
- Smaller revenue base of $796.9 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Negative returns on capital show that some of its growth strategies have backfired
At $2.29 per share, GoodRx trades at 7.3x forward P/E. To fully understand why you should be careful with GDRX, check out our full research report (it’s free).
One Stock to Watch:
Ollie's (OLLI)
Trailing 12-Month Free Cash Flow Margin: 7.3%
Often located in suburban or semi-rural shopping centers, Ollie’s Bargain Outlet (NASDAQ:OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts.
Why Are We Positive On OLLI?
- Rapid rollout of new stores to capitalize on market opportunities makes sense given its strong same-store sales performance
- Comparable store sales rose by 3.2% on average over the past two years, demonstrating its ability to drive increased spending at existing locations
- Expected revenue growth of 13.4% for the next year suggests its market share will rise
Ollie’s stock price of $94.81 implies a valuation ratio of 21.1x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
